Fintel on MSN10h
Leerink Partners Upgrades Gilead Sciences (GILD)
Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
Gilead upgraded to outperform by Leerink on PrEP outlook
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
Solid Investment Potential: Buy Rating for Gilead Sciences Amid Positive Revenue Adjustments and Growth Commitment
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
FierceBiotech16h
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks, setting stage for pivotal program
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Gilead upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
ENDPOINTS NEWS9h
Gilead, Mer­ck­'s ex­per­i­men­tal long-act­ing HIV treat­ment heads to Phase 3
Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...
Weather Underground19h
Mount Gilead, NC Weather Conditions
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.